Evidence map›Paper›PMID 34757501›Full record

ArticleJournal of patient-reported outcomes2021

Translation and adaptation of the EORTC QLQ-LC 29 for use in Chinese patients with lung cancer.

Wei Dai, Yaqin Wang, Yangjun Liu, Xing Wei, Ahmed M Y Osman, Cecilia Pompili, Michael Koller, Qifeng Wang, Yi Wang, Jun Ge and 2 more

Open access · goldAbstract read
In one paragraph

Article in Journal of patient-reported outcomes, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 4 countries.

Wei Dai *Department of Thoracic Surgery, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.ORCID https://orcid.org/0000-0003-1650-1590
Yaqin Wang *Department of Thoracic Surgery, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.ORCID https://orcid.org/0000-0003-4373-7435
Yangjun Liu *Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.ORCID https://orcid.org/0000-0002-3540-5361
Xing WeiDepartment of Thoracic Surgery, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.ORCID https://orcid.org/0000-0002-3035-5633
Ahmed M Y OsmanSchool of Pharmaceutical Science and Technology, Tianjin University, Tianjin, China.ORCID https://orcid.org/0000-0002-9068-2513
Cecilia PompiliSection of Patient Centred Outcomes Research, Leeds Institute for Medical Research at St James's, University of Leeds, Leeds, UK.ORCID https://orcid.org/0000-0001-6746-5441
Michael KollerCenter for Clinical Studies, University Hospital Regensburg, Regensburg, Germany.
Qifeng WangDepartment of Radiation Oncology, Sichuan Cancer Hospital & Institution, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.ORCID https://orcid.org/0000-0001-8544-9007
Yi WangDepartment of Radiation Oncology, Sichuan Cancer Hospital & Institution, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Jun GeDepartment of Medical Oncology, Sichuan Cancer Hospital & Institution, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Tianpeng XieDepartment of Thoracic Surgery, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China. drxietianpeng@163.com.
Qiang LiDepartment of Thoracic Surgery, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China. liqiang@sichuancancer.org.ORCID http://orcid.org/0000-0003-1841-4132
University of Electronic Science and Technology of China · CNKarolinska Institutet · SETianjin University · CNUniversity Hospital Regensburg · DEUniversity of Leeds · GB

Funding

Chengdu Science and Technology Project 2019-YF09-00234-SN
6 · The paper itself

Abstract

backgroundThe latest European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Lung Cancer 29 (QLQ-LC29) has been translated and validated in several languages but not yet in simplified Chinese. This study aimed to translate this questionnaire into simplified Chinese and adapt it for use in Chinese patients with lung cancer.

methodsThe translation and adaptation process followed the EORTC translation procedure, and consisted of eight steps, namely, translation preparation, forward translations, reconciled translation, back translations, a back translation report, proofreading, pilot testing, and finalisation. The pilot testing included 10 patients with lung cancer.

resultsWe obtained the permission to perform the EORTC QLQ-LC29 translation work on November 17, 2020. Thereafter, it took 3 weeks to complete the forward translations, reconciled translation, and back translations. After several rounds of discussion with the EORTC Translation Unit, 19 items used the existing translations from the EORTC Item Library (a database of EORTC questionnaire items and their translations), and 10 items were translated from scratch. The 10 patients included in the pilot testing phase had a median age of 64 years (range 31-69 years); five were male, five had an educational level of high school or above, and six had undergone surgery. Eight items received comments from patients (six items by one patient alone and the other two items by three patients). No patients commented on the instructions or the format used for responses. After discussion with the EORTC Translation Unit, we modified the Chinese wording in item 50 to ensure that the meaning of "lifeless" was clear. No changes were made to the remaining items.

conclusionsThe simplified Chinese version of the EORTC QLQ-LC29 is now available on the EORTC website. This translation may contribute to the application of the EORTC QLQ-LC29 scale in both research and clinical practice in the Chinese population with lung cancer. Further evaluation of the psychometric properties of the translated EORTC QLQ-LC29 is warranted.

Indexed as

Cultural adaptationLC29Lung cancerQuality of lifeSimplified ChineseTranslation

Identifiers

PMID34757501
PMCPMC8581083
OpenAlexW3159879411

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.